Favorable MARIPOSA information reveals capacity of amivantamab in EGFR-mutated NSCLC

MADRID– In this video, Julia Rotow, M D, scientific director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, went over MARIPOSA information on amivantamab in EGFR– altered sophisticated lung cancer provided at ESMO Congress.

Main arise from MARIPOSA, a stage 3, worldwide, randomized, managed trial, revealed that amivantamab (Rybrevant, Janssen) plus lazertinib (Leclaza; Yuhan, Janssen) was statistically exceptional to osimertinib (Tagrisso, AstraZeneca) in clients with EGFR– altered sophisticated NSCLC.

In MARIPOSA-2, scientists discovered that both amivantamab plus chemotherapy and amivantamab plus lazertinib plus chemotherapy enhanced PFS, unbiased reaction rate and intracranial PFS compared to chemotherapy alone in EGFR– altered sophisticated NSCLC after development on osimertinib.

Recommendations:

• Cho B, et al. Abstract LBA14. Provided at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
• Passaro A, et al. Abstract LBA15. Provided at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.

Released by:

Include subject to email notifies.

Get an e-mail when brand-new posts are published on

Please offer your e-mail address to get an e-mail when brand-new posts are published on

” data-action= subscribe>>.
Subscribe.

We were not able to process your demand. Please attempt once again later on. If you continue to have this problem please contact [email protected]

Back to Healio

Take Houses in Lung Cancer